Alzamend Neuro, Inc.
Alzamend Neuro, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I Disorder on December 15, 2026. There are 2 upcoming events on record.
Cash runway is approximately 20 months based on the most recent reported cash position and quarterly operating burn as of 2026-07-31.
| Date | Event | Type | Phase |
|---|---|---|---|
| December 15, 2026 | A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I Disorder | Trial Milestone | Phase 1/Phase 2 |
| March 3, 2028 | Study in Subjects With Mild-to-Moderate Alzheimer's Dementia | Trial Milestone | Phase 1/Phase 2 |
Track ALZN alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open ALZN in the tracker| Date | Event | Type | Phase |
|---|---|---|---|
| September 29, 2026 | 8-K filed: Reg FD disclosure | Filing | — |
| August 3, 2026 | 8-K filed: Material agreement, Listing / standard notice | Corporate | — |
| July 21, 2026 | 8-K filed: Other event | Filing | — |
| March 20, 2026 | 8-K filed: Listing / standard notice | Corporate | — |
| March 6, 2026 | 8-K filed: Material agreement | Corporate | — |
| December 15, 2025 | A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Healthy Adult Subjects | Trial Milestone | Phase 1 |
| November 18, 2025 | 8-K filed: Other event | Filing | — |
| July 23, 2025 | Quarterly results filed (8-K) | Earnings | — |
| May 8, 2025 | 8-K filed: Reg FD disclosure | Filing | — |
| April 14, 2023 | Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult Subjects | Trial Milestone | Phase 1/Phase 2 |
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.